Main Title |
Genotoxicity of Inhibitors of DNA Topoisomerases I (Camptothecin) and II (m-AMSA) In vivo and In vitro. |
Author |
Backer, L. C. ;
Allen, J. W. ;
Harrington-Brock, K. ;
Campbell, J. A. ;
DeMarini, D. M. ;
|
CORP Author |
Health Effects Research Lab., Research Triangle Park, NC. Genetic Toxicology Div. ;Environmental Health Research and Testing, Inc., Research Triangle Park, NC. |
Publisher |
c1990 |
Year Published |
1990 |
Report Number |
EPA/600/J-90/421; |
Stock Number |
PB91-171769 |
Additional Subjects |
Enzyme inhibitors ;
Mutagens ;
Camptothecin ;
Amsacrine ;
DNA topoisomerase I ;
DNA damage ;
Mutagenicity tests ;
In vitro analysis ;
In vivo analysis ;
Lymphoma ;
Chromosome aberrations ;
Cell cycle ;
Thymidine linase ;
Cultured tumor cells ;
Adenosine cyclic monophosphate ;
Reprints ;
|
Holdings |
Library |
Call Number |
Additional Info |
Location |
Last Modified |
Checkout Status |
NTIS |
PB91-171769 |
Some EPA libraries have a fiche copy filed under the call number shown. |
|
07/26/2022 |
|
Collation |
9p |
Abstract |
The present study was designed to determine and compare the clastogenicity of amsacrine and camptothecin in vivo in mouse bone marrow and peripheral blood lymphocytes and in vitro in mouse lymphoma L5178Y cells. It was expected that amsacrine, which interferes with topoisomerase II to induce double-strand DNA breaks, and camptothecin, which interferes with topoisomerase I to induce single-strand DNA breaks, would induce different types of chromosomal aberrations. However, both drugs produced quantitatively and qualitatively similar numbers and types of aberrations under similar experimental conditions. In mouse bone marrow, both drugs (3 mg/kg) induced about 30% damaged cells, with an average of 0.4 chromatid breaks per cell. Cell cycle specificity was indicated by the absence of chromosomal aberrations when exposure to the drugs occurred during GO in vivo. In vitro, amsacrine, and camptothecin induced 161 and 20 mutants/10 (to the sixth power) survivors/nM, respectively; they induced 6 and 2 aberrant cells/nM, respectively. In contrast to the in vivo results, the drugs induced high levels of both chromatid- and chromosome-type aberrations in vitro. |
Supplementary Notes |
Pub. in Mutagenesis, v5 n6 p541-547 1990. Prepared in cooperation with Environmental Health Research and Testing, Inc., Research Triangle Park, NC. |
NTIS Title Notes |
Journal article. |
Title Annotations |
Reprint: Genotoxicity of Inhibitors of DNA Topoisomerases I (Camptothecin) and II (m-AMSA) In vivo and In vitro. |
Category Codes |
57Y; 57F |
NTIS Prices |
PC A02/MF A01 |
Primary Description |
600/10 |
Document Type |
NT |
Cataloging Source |
NTIS/MT |
Control Number |
114324801 |
Origin |
NTIS |
Type |
CAT |